文献速递淋巴瘤

泼尼松、长春花碱、多柔比星和苯达莫司汀方案治疗老年初治霍奇金淋巴瘤的LYSA 2期研究

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
PubMed 文献 · Blood · 2024-01-01

这项多中心前瞻性2期研究评估PVAB方案(泼尼松、长春花碱、多柔比星、苯达莫司汀)治疗≥61岁晚期Ann Arbor分期初治经典型霍奇金淋巴瘤患者,89例可评估患者中完全代谢缓解率为77.5%(95%CI 67-86),中位随访42个月,4年无进展生存率和总生存率分别为50%和69%,毒性可接受。

要点

  • PVAB方案治疗老年初治经典型霍奇金淋巴瘤完全代谢缓解率为77.5%(95%CI 67-86)。
  • 中位随访42个月,4年无进展生存率和总生存率分别为50%和69%。
  • 肝脏受累、淋巴细胞减少、C反应蛋白和合并用药与无进展生存独立相关。

核心结论

  • PVAB方案在老年初治经典型霍奇金淋巴瘤患者中产生较高的完全代谢缓解率且毒性可接受,长期随访中生存终点受非淋巴瘤事件影响。

研究设计与样本

  • 多中心、前瞻性、2期研究,纳入89例新诊断经典型霍奇金淋巴瘤患者,年龄≥61岁且为晚期Ann Arbor分期。
  • 方案为每21天给予6个周期泼尼松(40 mg/m2,第1-5天)、长春花碱(6 mg/m2,第1天)、多柔比星(40 mg/m2,第1天)和苯达莫司汀(120 mg/m2,第1天)(PVAB方案)。
  • 年龄≥70岁患者以微型营养评估评分≥17为界值。
  • 主要终点为6个周期后的完全代谢缓解率。

主要发现

  • 89例纳入患者中位年龄68岁(范围61-88岁),35例(39%)年龄≥70岁,78例(88%)完成6个周期。
  • 毒性可接受,相关严重不良事件发生率为20%。
  • 69例(77.5%;95%CI 67-86)达到完全代谢缓解。
  • 中位随访42个月,31例(35%)进展或复发,24例(27%)死亡,其中霍奇金淋巴瘤11例、治疗期间毒性4例、第二肿瘤6例、其他原因3例。
  • 4年无进展生存率和总生存率分别为50%和69%;多因素分析显示肝脏受累(P=.001)、淋巴细胞减少(P=.001)、C反应蛋白(P=.0005)和合并用药(P=.003)与无进展生存独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Older patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, prospective, phase 2 study, we investigated a new firstline therapy regimen comprising 6 cycles of prednisone (40 mg/m2, days 1-5), vinblastine (6 mg/m2, day 1), doxorubicin (40 mg/m2, day 1), and bendamustine (120 mg/m2, day 1) (PVAB regimen) every 21 days for patients with newly diagnosed cHL aged ≥61 years with an advanced Ann Arbor stage. A Mini Nutritional Assessment score ≥17 was the cutoff value for patients aged ≥70 years. The primary end point was the complete metabolic response (CMR) rate after 6 cycles. The median age of the 89 included patients was 68 years (range, 61-88 years), with 35 patients (39%) aged ≥70 years. Seventy-eight patients (88%) completed the 6 cycles. The toxicity rate was acceptable, with a 20% rate of related serious adverse events. CMR was achieved by 69 patients (77.5%; 95% confidence interval [CI], 67-86). After a median follow-up of 42 months, 31 patients progressed or relapsed (35%), and 24 died (27%) from HL (n = 11), toxicity during treatment (n = 4), secondary cancers (n = 6), or other causes (n = 3). The 4-year progression-free survival (PFS) and overall survival rates were 50% and 69%, respectively. Multivariate analysis showed that liver involvement (P = .001), lymphopenia (P = .001), CRP (P = .0005), and comedications (P = .003) were independently associated with PFS. The PVAB regimen yielded a high CMR rate with acceptable toxicity. Over long-term follow-up, survival end points were influenced by unrelated lymphoma events. This trial was registered at www.clinicaltrials.gov as #NCT02414568 and at EudraCT as 2014-001002-17.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ghesquières H, Krzisch D, Nicolas-Virelizier E, et al. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients. Blood. 2024. PMID: 37979133. doi:10.1182/blood.2023021564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。